REGENXBIO Q2 net loss $68.2M, revenues up 48%; RGX-314 BLA on track for 2024

REGENXBIO Inc.

2022-Q2 EPS reported -$3.37 revenue$54,867,000

Net loss $68.2M ($1.58/share) vs $57.6M ($1.36) in Q2 2021; revenues $32.6M up 48% YoY.
Cash and marketable securities $682M (down from $849M Dec 2021); runway into 2025.
RGX-314 (wet AMD/DR) on track for BLA in 2024; pivotal trials enrolling; AAVIATE Cohort 5 complete; ALTITUDE enrollment complete.
RGX-121: intend to file BLA in 2024 via accelerated approval; pivotal CAMPSIITE trial active enrolling up to 10 patients.
RGX-202 first patient dosing expected in first half 2023; NAV licensee Zolgensma Q2 sales $379M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.